Avant Immunotherapeutics to Host Conference Call Today, April 16, 2008, at 5:00 PM to Discuss CDX-110 Partnership with Pfizer Inc.

NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will hold a conference call today at 5:00 PM ET to discuss today’s announcement of an exclusive worldwide licensing and development agreement between AVANT, acting through its wholly-owned subsidiary Celldex Therapeutics, Inc., and Pfizer for CDX-110. CDX-110, a therapeutic cancer vaccine candidate, is in Phase 2 development for the treatment of glioblastoma multiforme (GBM).
MORE ON THIS TOPIC